Tryp Therapeutics Explores Psilocybin's Potential In New Trials To Treat IBS And Fibromyalgia
Tryp Therapeutics Explores Psilocybin's Potential In New Trials To Treat IBS And Fibromyalgia
Tryp Therapeutics在治療腸易激綜合徵和纖維肌痛的新試驗中探索迷幻藥的潛力
Psychedelics biotech Tryp Therapeutics (OTCQB:TRYPF) is advancing its psilocybin-based portfolio through several recent milestones.
迷幻藥生物技術公司Tryp Therapeutics(OTCQB: TRYPF)正在通過最近的幾個里程碑推進其基於迷幻藥的產品組合。
Upcoming Phase 1 For IV Psilocin
IV Psilocin即將推出的第一階段
First, the company received approval from the Australian Human Research Ethics Committee (HREC) for a Phase 1 study on its IV-infused psilocin, TRP-8803. To take place at the CMAX Phase 1 unit in Adelaide, Australia, the open-label study will assess the safety and pharmacokinetics (PK) of a single intravenous (IV) infusion of the psychedelic in nine healthy adults.
首先,該公司獲得了澳大利亞人類研究倫理委員會(HREC)的批准,可以對其注入靜脈注射的迷幻藥 TRP-8803 進行第一期研究。這項開放標籤研究將在澳大利亞阿德萊德的CMAX第一期研究室進行,將評估九名健康成年人單次靜脈注射(IV)迷幻藥的安全性和藥代動力學(PK)。
On a broader scale, the trial is designed to determine the optimal blood levels of psilocin to achieve the targeted psychedelic...
在更廣泛的範圍內,該試驗旨在確定psilo...
登入免費觀看全文
登入/註冊